<DOC>
	<DOCNO>NCT00496574</DOCNO>
	<brief_summary>The aim study assess effect specific immunotherapy ( SIT ) dust mite clinical symptom , reliever drug usage , inhale glucocorticosteroid usage , quality life , lung function , bronchial hyperreactivity methacholine , presence type allergy three year SIT child asthma .</brief_summary>
	<brief_title>Evaluation Efficacy House Dust Mite Immunotherapy Children With Bronchial Asthma</brief_title>
	<detailed_description>According Global Initiative Asthma treatment asthma base avoidance allergen , pharmacological treatment , specific immunotherapy . The aim study assess effect specific immunotherapy ( SIT ) dust mite clinical symptom , reliever drug usage , inhale glucocorticosteroid usage , quality life , lung function , bronchial hyperreactivity methacholine , presence type allergy three year SIT child asthma .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>patient allergic house dust mites patient moderate bronchial asthma patient control asthma patient qualify immunotherapy give write informed consent immunotherapy ( active treatment group ) patient qualify immunotherapy agree kind treatment give write informed consent immunotherapy ( control group ) patient allergic perennial seasonal allergen patient chronic disease either put patient risk participate study could influence result study patient 's ability participate study judge investigator medication result patient exclusion include : antiparasites oral corticosteroid within 6 month first visit .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>asthma</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>efficacy</keyword>
	<keyword>child</keyword>
	<keyword>symptom score</keyword>
	<keyword>quality life</keyword>
	<keyword>spirometry</keyword>
	<keyword>PC20M</keyword>
</DOC>